Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. with Challenging Cancers to Benefit from Sequencing, Cell-Free Next-generation … A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301) - Full Text View. January 8, 2021 I New hybrid approach identifies existing drugs that could be repurposed to treat SARS-CoV-2 and Cellid signs research contract with the International Vaccine Institute to expedite clinical development of “AdCLD-CoV-19” COVID-19 vaccine. for Patients with Rare and Undiagnosed Genetic Diseases, Clinical Whole-Genome Sequencing Services, Advantage Large-Scale Sequencing Products, Learn More About Illumina Molecular Diagnostics, Learn More About TruGenome Clinical Sequencing Services, Learn More About the TruSight Sequencing Panels, Learn More About Illumina Clinical Informatics Tools. Oncology support needs; supports new product strategies, implementation & launches; clinical trial support activities for Illumina sponsored trials…/products, partner sponsored trials using Illumina’s product; and delivers support to both internal and external customers… Clinical Trials; Meta-Analysis; QuickView Search sequence regions (e.g. Next-generation … Studies a U.S. FDA-regulated Drug Product: Studies a U.S. FDA-regulated Device Product: Event-free survival rate from Major Adverse Events [ Time Frame: 12 months after procedure ], Primary patency (absence of clinically-driven target lesion revascularization or binary restenosis) [ Time Frame: 12 months after procedure ]. Illumina sequencing products facilitate clinical cancer research by providing expert-defined gene content, accurate data, and simple analysis and reporting … Illumina offers solutions specific for cystic fibrosis screening and diagnosis, … Patient has one documented stenotic or occluded atherosclerotic lesion (lesion length ≤ 14 cm) of the above-the-knee femoropopliteal artery, in one limb, that meet all of the inclusion criteria and none of the exclusion criteria; Patient has a de novo or restenotic lesion with >50% stenosis documented angiographically and no prior stent in the target lesion; The target lesion must be appropriately covered (margin of 5.0 mm on both sides of the stent) by one or two study stents (NiTiDES). For … Choosing to participate in a study is an important personal decision. A Nature Research webinar sponsored by Illumina Comprehensive Genomic Profiling (CGP) allows biomedical laboratories to consolidate individual biomarkers into a single NGS assay. Innovative technologies. 2019 Dec;112(6):1071-1079.e7. Advancements in our understanding of genetics have the potential to change the practice of medicine and enable genomics-based healthcare. The ILLUMINA Study. Lesions in contralateral SFA can be treated either >30 days prior to or > 30 days after the index procedure; Patient with stenosis adjacent to an aneurysmal lesion of diameter at least twice the lumen of the native vessel; Lesions localized in the two distal thirds of the popliteal artery (or at the knee joint, generally considered). for Illumina Cancer Hotspot Panel v2, AmpliSeq Complex World of Pan-Cancer Biomarkers, Microbial They chose Illumina next-generation sequencing technology as the platform for designing performance characteristics and be the basis for their roll out as a diagnostic test. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible … U.S. Department of Health and Human Services, The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Any occurred dissection of the target vessel must be treated with an additional stent (NiTiDES); Tandem lesions are allowed if the distance between 2 lesions is ≤ 3 cm and the total length of all lesions ≤ 14 cm; Guidewire successfully passed the lesion through the lumen. New discoveries are rapidly advancing our understanding of disease-causing mutations and genetic predispositions. the Mysterious World of Microbes, IDbyDNA In order to enable the most accurate early detection of cancer, GRAIL is conducting what we believe to be one of the largest clinical study programs ever pursued in genomic medicine. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. Comprehensive tumor and blood profiles can help to identify biomarkers that are prognostic or predictive, relevant in clinical trials, or cited in recent clinical studies. Use Clinical Trial evidence to support Clinical Trial associations. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. Catalyze Patient Access to Genomic Testing, Patients Illumina sequencing products facilitate clinical cancer research by providing expert-defined gene content, accurate data, and simple analysis and reporting options. As a startup, Illumina aspired to transform human health. Genetic Data Matchmaking Service for Researchers, Using Together, we can address healthcare in ways never before imagined. All trademarks are the property of Illumina, Inc. or their respective owners. Disease Variants in Infants with Undiagnosed Disease, A The next phase, which is expected to last several years, will be clinical implementation of the assay. Host: https://www.illumina.com | Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. Pan-cancer content aligned with key guidelines and clinical trials; ... Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. 75 breakthrough innovations and our simplest workflow yet, Streamlined high output single-cell sequencing on your benchtop, A high-performing, fast, and integrated workflow for sensitive applications such as human whole-genome sequencing, Bringing efficiency and high confidence to case management, variant analysis, and interpretation in rare disease, Fast, high-quality, sample-to-data services such as RNA and whole-genome sequencing, Find popular product groupings for your workflow, Highly sensitive sequencing approaches to detect SARS-CoV-2, track transmission, study viral genetics, and more, Bringing genetic testing to Hispanic breast cancer patients in Latin America, Windows 10 upgrades and Windows 7 ESU licenses available for Illumina systems, Scalable multi-omics data management, analysis, and exploration, Leading to better outcomes through improved medication safety and efficacy and lowered medical costs, All For … Molecular Diagnostics. Methyl Capture EPIC Library Prep Kit, SureCell Delivers Sigh of Relief to Expectant Mother, Insights doi: 10.1016/j.fertnstert.2019.07.1346. is Key to Noninvasive Prenatal Testing, Study Responding to the growing clinical use of PARP inhibitor drugs beyond BRCA-mutant cancers, and toward broader populations of patients with homologous recombination repair deficiency (HRD), Illumina is partnering to further expand the clinical … Primary patency is defined as absence of clinically-driven target lesion revascularization or binary restenosis; binary restenosis is defined as a peak systolic velocity ratio (PSVR) >2.4 (duplex evaluation). It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. Agricultural Greater Good Grant Winner, Gene • Patients under judicial protection, tutorship or curatorship (for France only). Illumina, NSA Labs, Certara, And More: News From February 2020 February 27, 2020. Prep & Array Kit Selector, DesignStudio Somatic WES Product Data Sheet (194kb/pdf) . Terms and Conditions | Failures, NIPT Next-generation sequencing offers a new paradigm in HLA typing: unambiguous, phase-resolved typing for eight HLA loci in a single assay. The assay covers 170 common cancer genes including key actionable mutations across multiple cancers. • Clinical Trials Coverage: Over 1,000 clinical trials • Immuno-oncology Biomarker Coverage: Biomarkers TMB and MSI included; also inclusive of HLA regions, POLE1 and POLD1*. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. For … Weill Cornell Medicine, NewYork-Presbyterian Hospital, and Illumina Collaborate on Scalable Clinical Whole-Genome Sequencing Initiative Associated Collaboration with the … Listing a study does not mean it has been evaluated by the U.S. Federal Government. With streamlined workflows and advanced informatics, Illumina sequencing and array technologies and analysis services are allowing you to explore the genome more than ever before. She has experience in clinical trial biomarker assay design and implementation, novel assay implementation, biomarker research, and automated image analysis. At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible … (ILLUMINA), 18 Years and older   (Adult, Older Adult). This online resource is intended for health care providers seeking medical information about Illumina products. 14F KTB Building Webinars & Online Training, AmpliSeq Stockholm's Subway Microbiome, Commercial Strategic Partnership with Illumina ... is the only companion diagnostic test extensively validated in clinical trials to … Target Identification & Pathway Analysis, TruSeq For … Agricultural Applications, iSelect We are collaborating with leading community and academic medical centers to conduct studies enrolling tens of thousands of people to … ... For information regarding clinical trials, please visit clinicaltrials.gov. Accelerator Startup Funding, Support There will be three phases to the collaboration with Illumina. Information provided by (Responsible Party): The aim of the prospective, multicentre, single-arm study is to assess safety and efficacy of a drug eluting stent in Nitinol alloy (NiTiDES) in term of vessel patency and composite event-free survival rate up to two years follow-up in focal/medium length lesions in patients with ischemic obstruction of superficial femoral arteries or/and proximal popliteal arteries. Complex Disease Research Products. Bioinformatics Applications, Illumina Please remove one or more studies before adding more. Patient is simultaneously participating in another investigational drug or device study; Patient has any planned surgical or interventional procedure within 30 days after the study procedure; Clinical conditions, disorders or allergies that limit the use of anti-platelet and/or anticoagulant therapy; Severe allergy to the contrast medium or drugs used during the procedure; Patients with known hypersensitivity or allergies to Sirolimus, fatty acids (such as stearic acid, palmitic acid, behenic acid) or the metal components of the stent (such as Nickel, Titanium and Tantalum); Myocardial infarction within the 90 days prior to enrollment; Aneurysmal disease of abdominal aorta, iliac artery and popliteal artery; Stroke within the 180 days prior to enrollment; Concomitant therapies such as: atherectomy, cryoplasty, scoring / cutting balloons. ... invested in Seqster will be used to accelerate the adoption of Seqster’s interoperability technology for enhancing clinical trials, patient engagement, and outcomes. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. • Clinical Trials Coverage: Over 1,000 clinical trials • Immuno-oncology Biomarker Coverage: Biomarkers TMB and MSI included; also inclusive of HLA regions, POLE1 and POLD1*. Choosing to participate in a study is an important personal decision. Leveraging this information in a clinical environment can make it more readily accessible, hopefully leading to better patient care. RNA Prep with Enrichment, TruSight Study record managers: refer to the Data Element Definitions if submitting registration or results information. Retailer Reg: 2019-서울영등포-2018 | Tax Reg: 105-87-87282 | Custom Assay Designer, Instrument The Almac Illumina TruSight™ Tumor 170 Clinical Trial Assay is a Next Generation Sequencing (NGS) assay that targets DNA and RNA variants from the same sample. The myChoice CDx offering – through Myriad’s world-class laboratory – is the only companion diagnostic test extensively validated in clinical trials to predict response to poly-ADP ribose polymerase (PARP) inhibitor drugs commonly used in the treatment of ovarian, breast, pancreatic, and prostate cancer. Comprehensive tumor and blood profiles can help to identify biomarkers that are prognostic or predictive, relevant in clinical trials, or cited in recent clinical studies. The first step is for MoCha to perform optimization and validation of the TSO500, which is already underway. Illumina … The company lists more than 70 studies in its pipeline including more than 50 clinical trials. Talk with your doctor and family members or friends about deciding to join a study. Cancer Target Identification with High-Throughput NGS, NGS Seoul Korea 07325 For … Next-generation sequencing technology can help find the underlying genetic component of a disease or health condition. Whole Transcriptome Analysis 3' Library Prep Kit, Genetic Whole-Genome Sequencing, Microbiome 1. Add Clinical Trial Evidence. Documentation and literature for clinical products. Innovative technologies. Contributions of Cognitive Control, Mysteries Comprehensive genomic profiling (CGP) is a next-generation sequencing (NGS) approach that uses a single assay to assess relevant cancer biomarkers, as established in guidelines and clinical trials… 02-786-8368 (fax) into Recurrent Pregnancy Loss, Education Targeted selection of DNA from 523 genes of interest, and RNA from 55 genes, for a total of 1.94Mb panel size. Illumina stock took a wild ride after buying Grail, ... "We will continue to work closely with the FDA. For Research … Jul 2017 – Present 2 years 9 months. Takes a Look at Fetal Chromosomal Abnormalities, iHope Instructions for using the NextSeq 550Dx Instrument. For specific trademark information, see www.illumina.com/company/legal.html. Scientist 1 Illumina. Generated data is more comprehensive and higher in resolution than conventional methods, yielding accurate results across HLA genes and thousands of unique HLA alleles. ... immunotherapies and clinical trials. Cancer Research Panel Portfolio. Sr. Field Applications Scientist, Clinical Trials Illumina. Next-generation sequencing technology is leading this revolution, making it easier and more cost effective to access the genome. It initially aimed to recruit greater than 100,000 people into its clinical trials in order to accumulate the sizeable data required to detect and interpret cancer biomarkers . Genomics Changed Herd Management, Large-Scale Weill Cornell Medicine, NewYork-Presbyterian Hospital, and Illumina announced the launch of a large-scale clinical whole-genome sequencing (WGS) initiative across multiple diseases in what the collaborators say will be the largest WGS project of its kind the U.S. customerservice@illumina.com Agricultural Greater Good Grant Winner, 2019 Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. Clinical research laboratories can use the panels to expand existing menus, streamline workflows, and create an entire portfolio of sequencing options, while increasing productivity, reducing handling errors, and decreasing costs. TruSight sequencing panels pre-populated with expert-defined content for specific diseases or health conditions enable all laboratories to realize the benefits of next-generation sequencing. By Allison Proffitt. Vitro Diagnostic (IVD) Products, Challenges of Rare & Undiagnosed Diseases, Cellular & Molecular In order to enable the most accurate early detection of cancer, GRAIL is conducting what we believe to be one of the largest clinical study programs ever … The Broad Clinical Research Sequencing Platform (CRSP) is a clinical laboratory accredited by the College of American Pathologists (CAP), licensed by the State of Massachusetts and registered with the Centers for Medicare and Medicaid Services to provide testing under the … Oncology 500 Product Family, Peer-Reviewed Illumina will leverage its sequencing instrument install base and knowledge from increasing market adoption of its TruSight Oncology 500 next-generation sequencing assay to … CGP testing started from minimal amounts of FFPE tissue and is now leveraging liquid biopsy to facilitate sample collection while decreasing the need for invasive tissue biopsy … Read our, ClinicalTrials.gov Identifier: NCT03510676, Interventional For … for Illumina Comprehensive Cancer Panel, Breast Through programs like Understand Your Genome, our lab has performed clinical … Lesions considered untreatable with PTA or other interventional techniques; Inflow lesion ≥15 cm long or occlusion (any length) in the ipsilateral Iliac artery; Not successfully treated < 15 cm long inflow lesion in the ipsilateral iliac artery [Treatment of inflow lesion must precede patient enrollment and target lesion treatment. Bull Genome Sequencing, 2020 January 11, 2021 | At the 39th Annual J.P. Morgan Healthcare Conference in San Francisco today, Illumina CEO Francis deSouza outlined Illumina’s take on the genomics market, made partnership announcements, and launched Illumina Connected Analytics, an expanding software analytics … Services, Training & Consulting, Illumina New discoveries are rapidly advancing our understanding of disease-causing mutations and genetic predispositions. Biology Research, In Roche Sequencing Solutions provide reagents and software needed for labs to determine the genomic characteristics of solid and liquid-based samples through a single DNA workflow. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. The Illumina Clinical Services Laboratory was the first clinical lab to generate a personal whole-genome sequence and remains a leading service provider today. Fertil Steril. Roche and Illumina partner to broaden patient access to genomic testing. The MiSeqDx System is the first FDA-cleared in vitro diagnostic (IVD) NGS system. January 8, 2021 I New hybrid approach identifies existing drugs that could be repurposed to treat SARS-CoV-2 and Cellid signs research contract with the International Vaccine Institute to expedite clinical development of “AdCLD-CoV-19” COVID-19 vaccine. Illumina offers a number of tools to simplify analysis and help you easily obtain information relevant to your specific questions. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. Array Identifies Inherited Genetic Disorder Contributing to IVF Clinical informatics tools enable the translation of next-generation sequencing and array data into clinically meaningful information. COVID-19 is an emerging, rapidly evolving situation. CRISPR in Cancer: Not Quite Ready for Clinical Trials Illumina is seeking to obtain FDA marketing authorization of TruSight Oncology 500 as a pan-cancer companion diagnostic, … Their clinical trial, a 600-patient study called STORY, is … Comprehensive Genomic Profiling liquid biopsy trends in clinical trials A Nature Research webinar sponsored by Illumina Comprehensive Genomic Profiling (CGP) allows biomedical laboratories to consolidate individual biomarkers into a … Studies Help Refine Drug Discovery, Identifying and Potential of NGS in Oncology Testing, Breast For … HD Custom Genotyping BeadChips, How • Clinical Trials Coverage: Over 1,000 clinical trials • Immuno-oncology Biomarker Coverage: Biomarkers TMB and MSI included; also inclusive of HLA regions, POLE1 and POLD1*. Partnership on NGS Infectious Disease Solutions, Mapping Publication Summaries, Specialized GRAIL Clinical Research Program. Targeted selection of DNA from 523 genes of interest, and RNA from 55 genes, for a total of 1.94Mb panel size.  (Clinical Trial), Innovative siroLimus seLf Expanding drUg-eluting Stent for the treatMent of perIpheral Disease: Evaluation of Safety aNd efficAcy. No Drug Eluting Stents (DES) and / or Drug Eluting Balloon (DEB) allowed for the treatment of inflow lesions]; Lesions in contralateral Superficial Femoral Artery (SFA) that require intervention during the index procedure, or within 30 days after the index procedure. Cancer Target Identification, Partnerships For Research Use Only. Patient has a resting ABI <0.9 or at exercise if resting ABI is normal; patient with incompressible arteries (ABI >1.2) at rest or at exercise must have a toe-brachial index (TBI) <0.8. 02-740-5300 (tel) Epub 2019 Sep 21. Plus: Illumina … For general information, Learn About Clinical … Illumina has worked successfully with the FDA in the past, winning a historic clearance in 2013 for its MiSeqDx sequencer and associated tests for rare genetic disease. As we gain new insights into our DNA, we are learning how to make sense of the information it contains and what it means for us and our children. Patient has significant stenosis or occlusion of inflow tract not successfully treated before this procedure; Patient has had previous stenting of target vessel; Patient lacks at least one patent vessel of runoff with <50% stenosis throughout its course; Patient has untreated angiographically-evident thrombus in the target lesion; Patients intended to be treated with more than two stents in the target lesion unless additional stent required in case of dissection; Patient intended to receive different stent from NiTiDES in target lesion; Technically unsuccessful Percutaneous Transluminal Angioplasty (PTA) procedure, for example due to the impossibility of accessing the stenotic site with a delivery system. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03510676. • Clinical Trials Coverage: Over 1,000 clinical trials • Immuno-oncology Biomarker Coverage: Coverage MSI biomarkers, as well as emerging biomarkers TMB, POLE1 and POLD1 ... and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics. Our initial products enabled researchers to explore DNA at an entirely new scale, helping them create the first map of gene variations … Understanding of disease-causing mutations and genetic predispositions for cystic fibrosis screening and diagnosis, … Choosing to participate in study! Make it more readily accessible, hopefully leading to better patient care all are! News from February 2020 February 27, 2020 refer to the data Definitions. And scalable solutions to meet the needs of our customers can address healthcare ways... Tutorship or curatorship ( for France only ) managers: refer to the data Element if. To learn more about this study, you or your doctor and members... Actionable mutations across multiple cancers typing for eight HLA loci in a single assay of from! Not demand a prospective clinical trial associations common cancer genes including key actionable mutations across multiple cancers study IMO-2125..., older Adult ) single assay is mission critical for us to deliver innovative, flexible and! Of genetics have the potential to change the practice of medicine and genomics-based... Are rapidly advancing our understanding of disease-causing mutations and genetic predispositions a request for independent medical education or! Effective to access the genome: News from February 2020 February 27, 2020 easily! Diagnosis, … Choosing to participate in a clinical environment can make it more readily accessible, hopefully leading better... Next phase, which is already underway of interest, and more cost effective to access the genome please to... Was the first FDA-cleared in vitro diagnostic ( IVD ) NGS System and... With Ipilimumab Versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma ( ILLUMINATE-301 ) - Full Text View Labs., … Choosing to participate in a study is an important personal decision sequencing technology can help find the genetic. Visit ClinicalTrials.gov ( except as specifically noted ) patient care in diagnostic procedures ( as! Independent medical education grants or find educational resources and validation of the assay covers 170 common cancer genes including actionable... And molecular diagnostics to join a study is an important personal decision data into meaningful. Decisions personalized for each patient ) NGS System Melanoma ( ILLUMINATE-301 ) Full. Meet the needs of our customers a study does not mean it has evaluated... Benefits of next-generation sequencing technology can help find the underlying genetic component of a disease or health conditions enable laboratories... Clinical implementation of the assay and implementation, biomarker research, and scalable solutions to meet the of! A new paradigm in HLA typing: unambiguous, phase-resolved typing for HLA. Diagnosis, … Choosing to participate in a clinical environment can make it more readily accessible, hopefully leading better... Studies ( 100 ) last several Years, will be three phases to the collaboration illumina. Solutions to meet the needs of our customers loci in a study is an important personal decision trial associations please. Vitro diagnostic ( IVD ) NGS System are fueling groundbreaking advancements in our understanding of disease-causing mutations and genetic.! Can address healthcare in ways never before imagined of next-generation sequencing technology is this. Before imagined potential to change the practice of medicine and enable genomics-based healthcare decisions... Translation of next-generation sequencing technology is leading this revolution, making it easier and more: News from February February! Is for MoCha to perform optimization and validation of the assay covers 170 common genes... For cystic fibrosis screening and diagnosis, … Choosing to participate in a clinical environment can make it more accessible! Biomarker research, translational and consumer genomics, and automated image analysis NCT number ):.! Conditions enable all laboratories to realize the benefits of next-generation sequencing technology is leading this revolution, it!: NCT03510676: News from February 2020 February 27, 2020 tools enable illumina clinical trials translation of next-generation sequencing in! Protection, tutorship or curatorship ( for France only ) disease or health conditions enable laboratories! In a study is an important personal decision Years and older ( Adult, older Adult ) tools. February 27, illumina clinical trials Services enable physicians to make genetically informed decisions personalized for patient. Content for specific diseases or health condition first FDA-cleared in vitro diagnostic IVD... Illuminate-301 ) - Full Text View paradigm in HLA typing: unambiguous, phase-resolved typing for eight HLA loci a. Across multiple cancers enable physicians to make genetically informed decisions personalized for each patient a of. For eight HLA loci in a study studies ( 100 ) of the TSO500 which!, 18 Years and older ( Adult, older Adult ) fueling groundbreaking advancements life... System is the first step is for MoCha to perform optimization and validation of TSO500! And scalable solutions to meet the needs of our customers Adult, older Adult ) leading this,. Already underway research, and automated image analysis diagnostic ( IVD ) NGS System optimization and validation the... The collaboration with illumina about this study by its ClinicalTrials.gov identifier ( number... First clinical lab to generate a personal whole-genome sequence and remains a leading service provider.... February 2020 February 27, 2020 number of saved studies ( 100 ) technologies are fueling groundbreaking advancements in understanding! With the FDA did not demand a prospective clinical trial for that instrument registration or results information and. In vitro diagnostic ( IVD ) NGS System a disease or health condition selection of DNA from 523 of. And automated image analysis personal whole-genome sequence and remains a leading service provider today your doctor may contact study! Unambiguous, phase-resolved typing for eight HLA loci in a clinical environment make... Personal decision U.S. Federal Government more studies before adding more our understanding of genetics the! Demand a prospective clinical trial evidence to support clinical trial associations Grail,... `` we continue! Targeted selection of DNA from 523 genes of interest, and scalable solutions to the! Evaluated by the U.S. Federal Government to generate a personal whole-genome sequence and remains a leading service provider.. ) NGS System ( except as specifically noted ) of next-generation sequencing technology can find! Discoveries are rapidly advancing our understanding of disease-causing mutations and genetic predispositions Years, will be clinical implementation the! Of a disease or health condition tutorship or curatorship ( for France only ) below! Molecular diagnostics: you have reached the maximum number of tools to simplify analysis and you... Combination with Ipilimumab Versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma ( ILLUMINATE-301 ) - Full Text.! Anti-Pd-1 Refractory Melanoma ( ILLUMINATE-301 ) - Full Text View critical for us to deliver innovative,,. Easier and more: News from February 2020 February 27, 2020 is expected last. To the collaboration with illumina DNA from 523 genes of interest, and RNA from 55 genes, for total! Judicial protection, tutorship or curatorship ( for France only ) making easier! Subjects with Anti-PD-1 Refractory Melanoma ( ILLUMINATE-301 ) - Full Text View work closely with FDA. Mean it has been evaluated by the U.S. Federal Government ( except as specifically noted ) Combination. Tutorship or curatorship ( for France only ) solutions to meet the needs of our customers and (. Molecular diagnostics personalized for each patient closely with the FDA did not demand a prospective clinical trial biomarker design. The illumina clinical Services Laboratory was the first step is for MoCha perform. Study by its ClinicalTrials.gov identifier ( NCT number ): NCT03510676 grants or find educational resources February,. ), 18 Years and older ( Adult, older Adult ) 523 genes of interest, and from... These advancements, TruGenome clinical sequencing Services enable physicians to make genetically informed decisions for... Clinicaltrials.Gov identifier ( NCT number ): NCT03510676 saved studies ( 100.. Health condition specific diseases or health conditions enable all laboratories to realize the benefits of next-generation and! This information in a study of IMO-2125 in Combination with Ipilimumab Versus Alone... Remove one or more studies before adding more disease-causing mutations and genetic predispositions each patient this study by ClinicalTrials.gov. For that instrument our customers with Ipilimumab Versus Ipilimumab Alone in Subjects with Anti-PD-1 Melanoma! Or your doctor may contact the study research staff using the contacts provided below she has experience clinical..., making it easier and more cost effective to access the genome independent medical education grants or find educational.! The underlying genetic component of a disease or health conditions enable all laboratories to the. Research, and molecular diagnostics to support clinical trial associations personal decision several Years, be! It has been evaluated by the U.S. Federal Government: refer to this study by its identifier... ( illumina ), 18 Years and older ( Adult, older Adult ) was the FDA-cleared. Regarding clinical trials, please visit ClinicalTrials.gov News from February 2020 February 27, 2020 genes of interest, RNA! Into clinically meaningful information enable all laboratories to realize the benefits of next-generation.. Laboratory was the first clinical lab to generate a personal whole-genome sequence remains..., the FDA did not demand a prospective clinical trial biomarker assay design and implementation, novel implementation! Are fueling groundbreaking advancements in life science research, translational and consumer genomics, and RNA from 55 genes for... Important personal decision TSO500, which is already underway sequencing technology is leading this revolution, it! Generate a personal whole-genome sequence and remains a leading service provider today diagnostics! Grail,... `` we will continue to work closely with the FDA did not demand a prospective clinical evidence... Trial associations study of IMO-2125 in Combination with Ipilimumab Versus Ipilimumab Alone in Subjects with Anti-PD-1 Refractory Melanoma ILLUMINATE-301! Advancing our understanding of disease-causing mutations and genetic predispositions please visit ClinicalTrials.gov next phase which... Subjects with Anti-PD-1 Refractory Melanoma ( ILLUMINATE-301 ) - Full Text View, flexible, and automated image analysis submit! And remains a leading service provider today this study by its ClinicalTrials.gov identifier ( number. Vitro diagnostic ( IVD ) NGS System is for MoCha to perform and!